JSON
Groenheit R, Bacchus P, Galanis I, Sondén K, Bujila I, Efimova T, Garli F, Lindsjö OK, Mansjö M, Movert E, Pettke A, Rapp M, Sperk M, Söderholm S, Asin KV, Zanetti S, Karlberg ML, Bråve A, Blom K, Klingström J
Emerg. Infect. Dis. 29 (6) 1240-1243 [2023-06-00; online 2023-06-00]
We performed 2 surveys during 2022 to estimate point prevalences of SARS-CoV-2 infection compared with overall seroprevalence in Sweden. Point prevalence was 1.4% in March and 1.5% in September. Estimated seroprevalence was >80%, including among unvaccinated children. Continued SARS-CoV-2 surveillance is necessary for detecting emerging, possibly more pathogenic variants.
PubMed 37141616
DOI 10.3201/eid2906.221862
Crossref 10.3201/eid2906.221862